Although CD155 has been demonstrated to play a role in CD226 loss of expression via proteasomal degradation of CD226 [20], our results indicated no correlation between CD155 and CD226 expression in CRC with liver metastasis, suggesting the existence of other mechanisms that drive loss of CD226 expression in the TME. This evidence concerns the gene PVR and colorectal carcinoma.